Fennec Pharmaceuticals (TSE:FRX) Insider Sells C$206,160.00 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) insider Pierre Sayad sold 12,000 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of C$17.18, for a total transaction of C$206,160.00. Following the completion of the transaction, the insider owned 9,519 shares of the company’s stock, valued at approximately C$163,536.42. This represents a 55.76% decrease in their ownership of the stock.

Fennec Pharmaceuticals Stock Down 1.8%

Shares of Fennec Pharmaceuticals stock traded down C$0.32 on Tuesday, reaching C$17.10. The company’s stock had a trading volume of 234 shares, compared to its average volume of 1,258. The company has a market capitalization of C$599.65 million, a P/E ratio of -142.50 and a beta of 3.72. The stock has a 50-day moving average price of C$15.48 and a 200-day moving average price of C$12.63. Fennec Pharmaceuticals Inc. has a 52-week low of C$7.59 and a 52-week high of C$17.64.

Institutional Trading of Fennec Pharmaceuticals

An institutional investor recently bought a new stake in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. purchased a new stake in shares of Fennec Pharmaceuticals Inc. (TSE:FRX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned about 0.30% of Fennec Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 15.40% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.